NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Microbiotica

Microbiotica

Private
CambridgeHealthcare & Life Scienceshttps://microbiotica.com/

Last Round

Series B

Mar 7, 2022

Est. Valuation

$118.5M

Total Funding Raised

$77.4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Microbiotica is a biotechnology company that develops live bacterial therapeutics and biomarkers based on microbiome science.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

microbiome therapeuticslive bacterial therapeuticsLBTmicrobiome discoverygut microbiomebioinformaticsimmuno-oncologyinflammatory bowel diseaseIBDdrug discoverymetagenomicsprecision medicinefecal microbiota transplantFMTbiotech platformgut healthbug drugs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Microbiotica Comparables

Compare Microbiotica with similar companies based on industry and business-model similarity.

Microbiotica comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
EnteroBiotix
87%
Exeliom Biosciences
84%
MRM Health
83%

Microbiotica Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 7, 2022
VC RoundOct 24, 2018
SeedDec 19, 2016

Key People

Founding team and executive leadership

Tim Sharpington

Chief Executive Officer

Executive Team

Stuart Gibson

Chief Financial Officer

Executive Team

Robert Tansley

Chief Medical Officer

Executive Team

Microbiotica Investors

Notable investors and investment history

Microbiotica investors
InvestorRounds
IP GroupSeries B, Seed
Flerie InvestSeries B
British Patient CapitalSeries B
British Patient CapitalSeries B
Cambridge Innovation CapitalSeries B, Seed
Flerie ABSeries B
Seventure PartnersSeries B, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2026

    Monthly visitors grew 101% MoM.

  • Jun 10, 2025

    Dr. Robert Tansley appointed as new Chief Medical Officer.

Microbiotica Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Microbiotica Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Microbiotica's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range55
Year Founded2016
Last FundingMar 7, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.